Pentixapharm's Underdevelopment Radiodiagnostic Gets Fast Track Designation From US FDA
Pentixapharm Holding's (PTP.F) development candidate [68Ga]Ga-PentixaFor secured a fast track designation from the US Food and Drug Administration. The status was granted for the diagnostic subtyping of adult patients with confirmed primary aldosteronism, the German clinical-stage radiopharmaceutical development company said Thursday.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.